3-(4-甲基-1-哌嗪基)苯甲酸 | 215309-01-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 3-(4-甲基-1-哌嗪基)苯甲酸
• 中文别名: 3-(4-甲基哌嗪)苯甲酸；3-(4-甲基-1-哌嗪)苯甲酸
• 英文名称: 3-(4-methyl-1-piperazinyl)benzoic acid
• 英文别名: 3-(4-Methylpiperazin-4-ium-1-yl)benzoate
• CAS: 215309-01-6
• 化学式: C₁₂H₁₆N₂O₂
• 分子量: 220.271
• InChiKey: HALATUFUWLWCQV-UHFFFAOYSA-N

物化性质

• 熔点：
  187-190 °C
• 沸点：
  400.2±40.0 °C(Predicted)
• 密度：
  1.188±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 2-8°C |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(4-Methylpiperazin-1-yl)benzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(4-Methylpiperazin-1-yl)benzoic acid
CAS number: 215309-01-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H16N2O2
Molecular weight: 220.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(4-甲基-1-哌嗪基)苯甲酸 在 草酰氯 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 11.0h， 生成
  参考文献：
  名称：

  作为潜在 TRK 抑制剂的新型四氢吡咯并[3,4-c]吡唑衍生物的设计、合成、生物学评价和药效团模型分析

  摘要：

  原肌球蛋白受体激酶 TRK 负责由NTRK基因融合引起的不同肿瘤类型，并已被确定为抗癌治疗的成功靶点。在此，我们通过合理的药物设计策略，从微摩尔效力的17a中报道了一种有效的选择性 TRKs 抑制剂19m 。化合物19m显着抑制TRK依赖性细胞系(Km-12)的增殖，而对TRK非依赖性细胞系(A549和THLE-2)没有抑制作用。此外，激酶选择性分析表明，除了TRK之外，化合物19m仅对ALK表现出较强的抑制活性。这些数据可能表明化合物19m具有良好的用药安全性。部分 ADME 特性在体外和体内进行了评估。化合物19m在大鼠药代动力学实验中表现出良好的AUC值和分布容积以及较低的清除率。最后，提出了以实验结果为指导的药效团模型。我们希望这个理论模型能够帮助研究人员更有效地寻找I型TRK抑制剂。

  DOI：

  10.1016/j.ejmech.2021.113627
• 作为产物：
  描述：

  氮芥 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 56.0h， 生成 3-(4-甲基-1-哌嗪基)苯甲酸
  参考文献：
  名称：

  Synthesis and serotonergic activity of variously substituted (3-amido)phenylpiperazine derivatives and benzothiophene-4-piperazine derivatives: novel antagonists for the vascular 5-HT1B receptor

  摘要：

  The synthesis and vascular 5-HT1B receptor activity of a novel series of substituted 3-amido phenylpiperazine and 4-(4-methyl-1-piperazinyl)-1-benzo[b]thiophene derivatives is described. Modifications to the amido linked sidechains of the 3-amidophenyl-piperazine derivatives and to the 2-sidechain of the 1-benzo[b]thiophene derivatives have been explored. Several compounds were identified which exhibited affinity at the vascular 5-HT1B receptor of pK(B) > 7.0. From the 3-aminophenyl-piperazine series, N-(4-(4-chlorophenyl)thiazol-2-yl-3-(4-methyl-1-piperazinyl)benzamide (30) and from the benzo[b]thiophene-4-piperazine series N-(2-ethylphenyl)-4-(4-methyl-1-piperazinyl)-1-benzo[b]thiophene-2-carboxamide (38) were identified as a highly potent, silent (as judged by the inability of angiotensin II to unmask 5-HT1B receptor mediated agonist activity in the rabbit femoral artery) and competitive vascular 5-HT1B receptor antagonist. The affinity of compounds from these two series of compounds for the vascular 5-HT1B receptor is discussed as well as a proposed mode of binding to the receptor pharmacophore. (C) 2004 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2003.12.008

文献信息

• PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
  申请人：Incyte Corporation

  公开号：US20180072720A1

  公开（公告）日：2018-03-15

  Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

  揭示了化合物的公式（I），使用这些化合物抑制HPK1活性的方法以及包含这些化合物的药物组合物。这些化合物在治疗、预防或改善与HPK1活性相关的疾病或紊乱方面是有用的，如癌症。
• Discovery of heterocycle-containing α-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors
  作者：Jinyun Dong、Guang Huang、Qing Cui、Qingqing Meng、Shaoshun Li、Jiahua Cui

  DOI：10.1016/j.ejmech.2020.112895

  日期：2021.1

  against CYP1 enzymes, leading to the identification of fluorine-containing compound 15i as the most potent and selective CYP1B1 inhibitor (IC50 value of 0.07 nM), being 84-fold more potent than that of the template molecule ANF. Alternatively, the amino-substituted derivative 13h not only possessed a potent inhibitory effect on CYP1B1 (IC50 value of 0.98 nM), but also had a substantially increased water

  细胞色素P450 1B1（CYP1B1）已被很好地验证为预防癌症和逆转耐药性的诱人靶标。为了继续关注这一领域，本文合成了一组在B环中不同的46个6,7,10-三甲氧基-α-萘黄酮衍生物，并针对CYP1酶进行了筛选，从而鉴定了含氟化合物15i作为最有效和选择性的CYP1B1抑制剂（IC 50值为0.07 nM），比模板分子ANF的效力高84倍。另外，氨基取代的衍生物13h不仅对CYP1B1具有强抑制作用（IC 50值（0.98 nM），但与铅ANF相比，其水溶性大大提高（13h为311μg/ mL，ANF为<5μg/ mL）。目前的研究扩大了CYP1B1抑制剂的结构多样性，化合物13h被认为是有希望的起点，具有进一步研究的巨大潜力。
• [EN] NEW AMINO-PYRIMIDONYL-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS D'AMINO-PYRIMIDONYL-PIPÉRIDINYL, LEUR PROCÉDÉ DE PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SERVIER LAB

  公开号：WO2020079205A1

  公开（公告）日：2020-04-23

  Compounds of formula (I) wherein R1, R2, R3, R4, R5, n and Q are as defined in the description. Medicaments.

  式(I)中R1、R2、R3、R4、R5、n和Q的化合物如描述中所定义。药物。
• Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
  申请人：Vanotti Ermes

  公开号：US20070112020A1

  公开（公告）日：2007-05-17

  The present invention is directed to compounds of the formula or pharmaceutically acceptable salts, prodrug, solvate or optical isomer thereof, pharmaceutical compositions containing same and use thereof for treating diseases linked to disregulated cell proliferation or to disregulated protein kinase.

  本发明涉及以下化合物的公式，或其药用盐、前药、溶剂化合物或其光学异构体，包含相同化合物的药物组合物以及用于治疗与细胞增殖失调或蛋白激酶失调相关疾病的用途。
• Protease inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US06518267B1

  公开（公告）日：2003-02-11

  The present invention provides bis-aminomethyl carbonyl protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

  本发明提供了双氨甲基羰基蛋白酶抑制剂及其药用可接受的盐、水合物和溶剂化物，其抑制蛋白酶，包括卡特普辛K，这些化合物的药用组合物，以及治疗骨量过度流失或软骨或基质降解疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说，是骨关节炎和类风湿关节炎；帕盖特病；恶性高钙血症；和代谢性骨病，包括通过向需要的患者给予本发明化合物来抑制骨量过度流失或软骨或基质过度降解。